Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19.[2][3][4][5] It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor.[6][7] It is taken by mouth.[8][9][10]
The most common adverse events include transient decreases in high-density lipoprotein and increases blood triglycerides.[8]
^Cite error: The named reference NHK WORLD 2024 was invoked but never defined (see the help page).
^McCarthy MW (December 2022). "Ensitrelvir as a potential treatment for COVID-19". Expert Opin Pharmacother. 23 (18): 1995–1998. doi:10.1080/14656566.2022.2146493. PMID 36350029. S2CID 253418404.
^Fujikawa M (22 November 2022). "Japan Approves First Homegrown Covid-19 Antiviral Pill". The Wall Street Journal. Retrieved 28 November 2022.
^"Shionogi's Covid antiviral lands first approval in Japan's new emergency approval pathway". Endpoints News. 22 November 2022. Retrieved 28 November 2022.
^"Xocova: Powerful New Japanese Pill for Coronavirus Treatment". BioPharma Media. February 2022.
^Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, et al. (May 2022). "Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19". Journal of Medicinal Chemistry. 65 (9): 6499–6512. doi:10.1021/acs.jmedchem.2c00117. PMC 8982737. PMID 35352927.
^"Shionogi presents positive Ph II/III results for COVID-19 antiviral S-217622". thepharmaletter.com. 31 January 2022.
^ ab"Xocova (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection, under the Emergency Regulatory Approval System". Shionogi (Press release). 22 November 2022. Retrieved 28 November 2022.
^"Shionogi's new COVID pill appears to ease omicron symptoms". Nikkei Asia. 21 December 2021.
^Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. (IASO study team) (May 2022). "Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2". Nature. 607 (7917): 119–127. Bibcode:2022Natur.607..119U. doi:10.1038/s41586-022-04856-1. PMC 10579982. PMID 35576972. S2CID 248833104.
Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19. It was developed by Shionogi in partnership...
treatment. Xofluza, an endonuclease inhibitor, for influenza treatment. Ensitrelvir (S-217622), the first Japanese domestic pill to treat COVID-19, yet to...